- Home
- MGNX vs IOBT Comparison
MGNX vs IOBT Comparison
Compare MGNX & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- IOBT
- Stock Information
- Founded
- MGNX 2000
- IOBT 2014
- Country
- MGNX United States
- IOBT Denmark
- Employees
- MGNX N/A
- IOBT N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- MGNX Health Care
- IOBT Health Care
- Exchange
- MGNX Nasdaq
- IOBT Nasdaq
- Market Cap
- MGNX 70.3M
- IOBT 62.6M
- IPO Year
- MGNX 2013
- IOBT 2021
- Fundamental
- Price
- MGNX $1.43
- IOBT $1.00
- Analyst Decision
- MGNX Hold
- IOBT Strong Buy
- Analyst Count
- MGNX 10
- IOBT 3
- Target Price
- MGNX $6.83
- IOBT $9.33
- AVG Volume (30 Days)
- MGNX 599.1K
- IOBT 83.8K
- Earning Date
- MGNX 05-20-2025
- IOBT 05-20-2025
- Dividend Yield
- MGNX N/A
- IOBT N/A
- EPS Growth
- MGNX N/A
- IOBT N/A
- EPS
- MGNX N/A
- IOBT N/A
- Revenue
- MGNX $149,962,000.00
- IOBT N/A
- Revenue This Year
- MGNX N/A
- IOBT N/A
- Revenue Next Year
- MGNX $80.86
- IOBT N/A
- P/E Ratio
- MGNX N/A
- IOBT N/A
- Revenue Growth
- MGNX 155.26
- IOBT N/A
- 52 Week Low
- MGNX $0.99
- IOBT $0.66
- 52 Week High
- MGNX $14.91
- IOBT $1.79
- Technical
- Relative Strength Index (RSI)
- MGNX 43.37
- IOBT 52.54
- Support Level
- MGNX $1.54
- IOBT $0.95
- Resistance Level
- MGNX $1.82
- IOBT $1.20
- Average True Range (ATR)
- MGNX 0.15
- IOBT 0.09
- MACD
- MGNX 0.01
- IOBT 0.01
- Stochastic Oscillator
- MGNX 19.79
- IOBT 43.10
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.